Floatz logo

FLUOROURACILUM

Peritoneal Carcinomatosis

Ciusss de L'Est de l'Île de MontréalSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Peritoneal Carcinomatosis cohort.

Asset / SponsorPhaseRating
Eloxatin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB
MITOMYCIN C
H. Lee Moffitt Cancer Center and Research Institute
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB

View all 42 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →